Meso scale discovery-based assays for the detection of aggregated huntingtin by Reindl, W et al.
RESEARCH ARTICLE
Meso scale discovery-based assays for the
detection of aggregated huntingtin
Wolfgang Reindl1, Barbara Baldo1, Jana Schulz1, Isabell Janack1, Ilka Lindner1,
Markus Kleinschmidt1, Yalda Sedaghat1, Christina Thiede1, Karsten Tillack1,
Christina Schmidt1, Isabell Cardaun1, Tom Schwagarus1, Frank Herrmann1,
Madlen Hotze1, Georgina F. OsborneID2, Simone Herrmann1, Andreas Weiss1,
Celina Zerbinatti1, Gillian P. Bates2, Jonathan Bard3, Ignacio Munoz-Sanjuan3,
Douglas MacdonaldID3*
1 Evotec AG, Hamburg, Germany, 2 Dept. Neurodegenerative Disease, Huntington’s Disease Centre and
Dementia Research Institute, Institute of Neurology, University College London, London, United Kingdom,
3 CHDI Management/CHDI Foundation, Los Angeles, CA, United States of America
* Douglas.Macdonald@chdifoundation.org
Abstract
Huntington’s disease (HD) is a monogenic neurodegenerative disorder caused by an expan-
sion of the CAG trinucleotide repeat domain in the huntingtin (HTT) gene, leading to an
expanded poly-glutamine (polyQ) stretch in the HTT protein. This mutant HTT (mHTT) pro-
tein is highly prone to intracellular aggregation, causing significant damage and cellular loss
in the striatal, cortical, and other regions of the brain. Therefore, modulation of mHTT levels
in these brain regions in order to reduce intracellular mHTT and aggregate levels represents
a direct approach in the development of HD therapeutics. To this end, assays that can be
used to detect changes in HTT levels in biological samples are invaluable tools to assess
target engagement and guide dose selection in clinical trials. The Meso Scale Discovery
(MSD) ELISA-based assay platform is a robust and sensitive method previously employed
for the quantification of HTT. However, the currently available MSD assays for HTT are pri-
marily detecting the monomeric soluble form of the protein, but not aggregated species. In
this study, we describe the development of novel MSD assays preferentially detecting
mHTT in an aggregated form. Recombinant monomeric HTT(1–97)-Q46, which forms
aggregates in a time-dependent manner, was used to characterize the ability of each estab-
lished assay to distinguish between HTT monomers and HTT in a higher assembly state.
Further validation of these assays was performed using brain lysates from R6/2, zQ175
knock-in, and BACHD mouse models, to replicate a previously well-characterized age-
dependent increase in brain aggregate signals, as well as a significant reduction of aggre-
gate levels in the striatum following mHTT knockdown with a CAG-directed allele-specific
zinc-finger repressor protein (ZFP). Lastly, size exclusion chromatography was used to sep-
arate and characterize HTT species from brain tissue lysates to demonstrate specificity of
the assays for the fractions containing aggregated HTT. In summary, we demonstrate that
the newly developed assays preferentially detect aggregated HTT with improved perfor-
mance in comparison to previous assay technologies. These assays complement the
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existing MSD platform assays specific for soluble HTT monomers, allowing for a more com-
prehensive analysis of disease-relevant HTT species in preclinical models of HD.
Introduction
Huntington’s disease (HD) is a neurodegenerative genetic disorder that leads to motor dys-
function and cognitive decline [1]. The neuropathology is most prominently characterized by
neuronal loss and atrophy of the caudate nucleus and putamen regions of the striatum [2, 3].
HD is caused by the abnormal expansion of CAG trinucleotide repeats within exon 1 of the
huntingtin (HTT) gene, which leads to the expansion of the poly-glutamine (polyQ) stretch
located in the N-terminus of the HTT protein [4].
The onset and severity of the disease correlates with the repeat length of the polyQ stretch:
individuals with 35 and less CAGs do not show any symptoms, while manifestation of the disease
starts from 36 CAGs onward [5]. The expanded polyQ stretch increases the propensity of the
HTT protein to form aggregates that accumulate within both the nucleus and cytoplasm of cells,
most prominently in neurons. The rate of mHTT aggregation is proportional to the increase in
CAG repeat length and age [6], and correlates with susceptibility to cell death and loss of neuronal
tissue [7, 8]. It has been previously shown that shutting down mHTT expression in a conditional
HD mouse model leads to the reduction of nuclear and extranuclear HTT aggregates, and to a
concomitant improvement of cognitive deficits [9]. Therefore, modulation of mHTT and mHTT
aggregate levels represents a promising therapeutic approach for HD patients. For this reason,
multiple HTT-lowering agents such as antisense oligonucleotides (ASO), small interfering RNAs
(siRNA), micro RNAs (miRNA), and zinc finger repression proteins (ZFP) are in or under devel-
opment for clinical testing based on promising results generated in preclinical models.
ASOs that catalyze RNase H-mediated degradation of HTT mRNA were reported to pro-
duce sustainable suppression of mHTT expression and prevent brain mass loss in HD rodent
models [10]. In addition, single-stranded siRNAs (ss-siRNAs) were also shown to efficiently
inhibit mHTT expression throughout the brain of heterozygous HdhQ150 mice [11]. Adeno-
associated virus (AAV)-mediated delivery of miRNAs has been reported to lower mHTT
expression, reduce aggregate levels and reverse disease symptoms in YAC128 mice [12]. AAV-
mediated delivery of shRNA against HTT also leads to marked reduction in HTT aggregate
levels in the transduced striatum of zQ175 mice [13]. A relatively new field is the application of
ZFPs that selectively target mutant HTT. In this context, AAV-mediated ZFP expression
reduces HTT aggregates and improves behavioral deficits in R6/2 and zQ175 mice [14, 15].
As these HTT-lowering therapies advance to clinical testing, assessing their value for HD
patients requires reliable assays that can be used to measure HTT levels in relevant biological
samples for assessment of target engagement and efficacy. Several assay systems using time-
resolved fluorescence resonance energy transfer (TR-FRET), ELISAs, ELISA-based Meso Scale
Discovery (MSD) electrochemiluminescence assays, or the Erenna Singulex platforms have
been developed for the quantification of soluble monomeric and mutant HTT protein species
[16–20]. Nonetheless, only a limited number of assays for selective and quantifiable detection
of oligomeric or aggregated HTT have been developed to date. For example, AGERA (agarose
gel electrophoresis for resolving aggregates) is a qualitative approach to assess HTT aggregates
in biological samples [21]. A Seprion ligand ELISA assay, which utilizes a proprietary aggre-
gate-capturing reagent, has been developed for detection of HTT aggregates [22]. In addition,
two homogeneous TR-FRET-based immunoassays were established for selective quantification
of HTT aggregates in cell and tissue homogenates [23].
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The MSD assay platform has emerged as a versatile, sensitive, and robust technique for
detection of HTT. Multiple combinations of capturing and detection antibodies allow for the
quantification of different forms of HTT [19]. Here, we describe the development of novel
MSD assays preferentially detecting aggregated HTT that complement the existing assays for
the quantification of soluble HTT monomers. These assays represent new platform tools for
the analysis of preclinical HD models. They could be used for measuring prevention of aggre-
gate formation and reversal of formed aggregates, or evaluation of HTT protein life cycle. As
an immuno-based assay system, the MSD technology requires the availability of selective anti-
bodies. MW8, a mouse monoclonal antibody generated against soluble and aggregated human
exon 1-Q67 as immunogen, has been previously applied for staining of HTT aggregates by
immunohistochemistry [24, 25] and aggregate detection by TR-FRET assays [23]. Using MW8
in various combinations with other anti-HTT antibodies, we were able to develop HTT aggre-
gation MSD assays that showed equal or improved performance in comparison to existing
assay technologies. These assays were able to detect a well-characterized age-dependent
increase in HTT aggregate signal in the brain of HD mouse models [13, 22, 26], and a signifi-
cant reduction in HTT aggregates after mHTT knockdown with ZFP in the zQ175 mouse stri-
atum [15]. Additionally, analysis of HD mouse brain homogenates after separation of HTT
monomers and aggregates by size exclusion chromatography confirmed the preferential aggre-
gate binding of the newly-developed assays. In summary, the novel aggregate-detecting MSD
assays developed here can be used to expand the available techniques for HTT detection and
allow for a more comprehensive analysis of HTT protein species in biological samples.
Materials and methods
Anti-HTT antibodies
Generation of the following antibodies was previously described: rabbit polyclonal antibody
CHDI-90000147 (pAb147) binding to amino acids 37–53 within the poly-proline domain of
mouse HTT [19]; mouse monoclonal antibody CHDI-90000895 (MW1) binding to the polyQ
stretch of HTT [24]; mouse monoclonal antibody CHDI-90000830 (2B7) binding to the N-ter-
minus of human HTT (amino acids 7–13) [16]; mouse monoclonal antibody CHDI-90000833
(4C9) binding against the poly-proline domain of human HTT (amino acids 51–71) [23]; S830
is a sheep polyclonal antibody that was raised against an exon 1 HTT protein with 53Q [27].
The mouse monoclonal antibody MAB2166, with the epitope mapped to amino acids 445–459
of the human HTT [28], was obtained from Millipore. The mouse monoclonal antibody
CHDI-90000942 (MW8) was generated using soluble human GST-tagged exon 1-Q67 boosted
with exon 1-Q67 aggregates; the epitope was mapped to amino acids 83–90 (AEEPLHRP) at
the C-terminus of human exon 1 HTT [24]. SULFO-TAG (ST) labeling of antibodies 4C9,
MW1, and MW8 was performed using the MSD SULFO-TAG NHS-Ester reagent (Meso Scale
Discovery) according to manufacturers’ instructions.
Recombinant huntingtin proteins
cDNA corresponding to the N-terminal 97 amino acids of human HTT including either 16 or
46 glutamine residues was cloned into a modified pTriEx-4 vector (Millipore) coding for an
N-terminal MBP and C-terminal His6 tag. The 97 amino acid N-terminal sequence represents
an extended version of the regular human exon 1 HTT sequence (amino acids 1–90) to include
a short spacer between the MW8 epitope and the C-terminal His6 tag. The goal was to prevent
the His6 tag from interfering with MW8 binding to HTT. The polyQ stretch was coded by a
mixed CAG/CAA composition to reduce the risk of deletion or expansion during propagation
and cloning. Proteins were expressed in E.coli BL21 (DE3). After lysis of cell pellets using a
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microfluidizer (Microfluidics), proteins were purified by sequential Ni-NTA and amylose
affinity chromatography, followed by dialysis against a buffer containing 10 mM Tris (pH 8.0)
and 100 mM NaCl. Proteins were concentrated using a 10 kDa MWCO Amicon Ultra spin
concentrator (Millipore). Following determination of protein concentration, purified HTT
protein (purity > 95%) was aliquoted and stored at -80˚C. The HTT constructs are referred to
as HTT(1–97)-Q16 and HTT(1–97)-Q46 throughout the publication. Human HTT(1–573)-
Q23 and Q73 with N-terminal FLAG tag [19] and human full-length HTT-Q17 and Q46 [29]
carrying an N-terminal FLAG and C-terminal His8 tag were provided by BioFocus, a Charles
River Company (Leiden, NL) and stored at -80˚C.
Generation of HTT aggregates, aggregation kinetics, and inhibition of
aggregation
The MBP-tag was introduced at the N-terminus of the HTT(1–97) constructs to maintain the
proteins in a soluble state. The thrombin cleavage site inserted between the tag and HTT allows
subsequent cleavage of the MBP-tag by thrombin protease, leading to the aggregation of HTT
(1–97). For generation of aggregates, 10 μM MBP-tagged HTT(1–97)-Q16 or Q46 were mixed
with 150 μg/mL bovine thrombin protease (Sigma) and 2 mM CaCl2 in a total volume of
200 μL 50 mM Tris (pH 8.0), 150 mM NaCl (aggregation buffer). Samples were incubated for
24 h at 37˚C. Cleaved proteins were aliquoted, snap-frozen, and stored at -20˚C and are stable
for up to 6 months.
For monitoring aggregation kinetics, the same aggregation samples were used in a total vol-
ume of 400 μL. Aliquots were analyzed before and at multiple time points after initiation of
aggregation by protease addition. Samples were immediately snap-frozen at each time point
and stored at -20˚C. Regarding concentrations of aggregated HTT(1–97)-Q46, assuming com-
plete aggregation after 24 h incubation, the concentration of aggregates was set equal to the
concentration of monomeric HTT before initiation of the aggregation process.
For inhibition of aggregation, protease cleavage and subsequent aggregation of 33 μM HTT
(1–97)-Q46 was performed in the presence of different concentrations of the known HTT
aggregation inhibiting peptide QBP1 and a scrambled (scr) QBP1 control [30]. Peptides car-
ried an Antennapedia (Antp)-tag [31]. The isolated Antp-tag was also included as control.
After 6 h of incubation at 37˚C, samples were snap-frozen and stored at -20˚C. For MSD anal-
ysis, samples were further diluted to 250 nM HTT(1–97)-Q46.
Rodent models
Fresh snap-frozen whole brain samples from R6/2 mice strain B6CBA-Tg(HDexon 1)62Gpb/3J at
4, 6, 8, and 12 weeks of age (CAG repeat sizes (mean ± standard deviation): 4 weeks: 120 ± 2.3; 6
weeks: 123 ± 0.6; 8 weeks: 116 ± 3.2; 12 weeks: 114 ± 1.2), zQ175 knock-in mice strain C57BL/6J
Htttm1Mfc/190JChdi at 3, 6, 9, and 14 months of age (CAG repeat sizes (mean ± standard devia-
tion): 3 months: 190 ± 6.0; 6 months: 187 ± 7.7; 9 months: 191 ± 3.0; 14 months: 186 ± 7.7), and
BACHD mice strain C57BL/6 Tg(HTT�97Q)LXwy/JChdi at 3, 6, 9, and 12 months of age were
(CAG repeat sizes stable at 97) obtained from the Jackson Laboratory (Bar Harbor, USA) and
stored at -80˚C until homogenization. Mice were euthanized by trained personnel by a lethal dose
of carbon dioxide (CO2) followed by cervical dislocation prior to tissue collection. All procedures
and protocols were run according to The Jackson Laboratory’s Institutional Animal Care and Use
Committee (IACUC) Guidelines, and were conducted in compliance with the National Institutes
of Health Guideline for Care and Use of Laboratory Animals.
Hemizygous R6/2 mice in the Bates Lab colony were maintained by backcrossing R6/2
males to (CBA/CaxC57BL/6J)F1 females (B6CBAF1/OlaHsd; Harlan Olac) and mice were
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genotyped and CAG repeat sized as previously described [22]. Mice were sacrificed by cervical
dislocation. Cortex, striatum, and musculus tibialis anterior samples from R6/2 and wild type
mice at 4, 8, and 14 weeks of age were dissected and snap frozen in liquid nitrogen. CAG repeat
sizes (mean ± standard deviation) were as follows: 4 weeks (209 ± 3.9), 8 weeks (210 ± 2.4) and
14 weeks (210 ± 3.3). In the Bates Lab, all experimental procedures performed on mice were
conducted under a license from the Home Office (Animal Scientific Procedures Act 1996) and
approved by the Ethical Review Process Committee.
The R6/2 mouse model is transgenic for a genomic fragment spanning the 5’ end of the
human HTT gene, including exon 1 [32, 33]. The zQ175 C57B/L6J knock-in mouse is derived
from a spontaneous expansion of the CAG copy number in the originally described CAG 140
knock-in mouse model [34, 35]. The BACHD mouse model expresses full-length human
mHTT with 97 glutamine repeats under the control of the endogenous HTT regulatory
machinery on the bacterial artificial chromosome [26].
AAV-ZFP in vivo application in an HD mouse model
Live zQ175 C57B/L6J knock-in mice and wildtype littermates were obtained from the Jackson
Laboratory (Bar Harbor, USA). Two groups of 10 zQ175 mice received bilateral intra-striatal
injections of viral particles encoding either the HTT allele-specific ZFP30640 or a control with-
out the DNA-binding domain (ZFP-ΔDBD) [15] at 2 months of age. Mice were individually
anaesthetized with 3% isoflurane at a flow rate of 1 L/min and placed in a small animal stereo-
taxic instrument (Kopf; Model No. 940). Anesthesia was maintained via gas nose cone delivery
of 2% isoflurane at a flow rate of 0.5 L/min throughout the surgical procedure. The scalp of the
animal was sterilized with 70% ethanol and iodine solution, followed by lidocaine application.
A longitudinal mid-sagittal incision of 1 cm in length was made in the scalp. Following skin
incision, a small hole corresponding to the striatal injection site was made in skull using an
electrical drill (Foredom; Model No. H.30). The coordinates measured according to the mouse
bregma were 0.8 mm anterior, 1.8 mm lateral on right and 3.8 mm deep from bregma with flat
skull nosebar setting. A total volume of 4 μL (4E10 genome copies (GCs)) ZFP viral particles
was administered using a Hamilton gas tight syringe (customized gauge 26 needle, model 1801
RN) connected to an automated microinjection pump with a constant flow rate of 200 nL/
min. After injection, the surgery wound was sealed and the animals were kept on a heating pad
until fully recovered. Mice were euthanized 4 months post-injection at 6 months of age. For
subsequent MSD analysis, mice were sacrificed by decapitation after exposure to carbon diox-
ide, striata were prepared from removed whole brains, snap-frozen, and stored at -80˚C until
homogenization. All animal work was carried out in accordance with the regulations of the
German animal welfare act and the EU legislation (EU directive 2010/63/EU). The study pro-
tocol was approved by the local Ethics committee of the Authority for Health and Consumer
Protection of the city and state of Hamburg (“Behörde für Gesundheit und Verbraucherschutz”
BGV, Hamburg) under the file number #V11307/591 00.33.
Tissue homogenization
Whole brain homogenates were lysed using a T25 ULTRA-TURRAX (IKA) with three 30 s
pulses in 5 mL tissue lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 10 mM NaF, 1 mM PMSF, Phosphatase Inhibitor
Cocktail II (Sigma), Phosphatase Inhibitor Cocktail III (Sigma), Protease Inhibitors (Roche
Diagnostics). Crude lysates were centrifuged three consecutive times for 12 min at 3,000 x g
and 4˚C, the supernatant was transferred to a new tube after each centrifugation step. Dis-
sected cortex, striatum and musculus tibialis anterior samples were homogenized in 250–
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400 μL tissue lysis buffer using lysing matrix M tubes (MP Biomedicals), striatal samples of
ZFP-treated mice were homogenized in 80 μL of tissue lysis buffer using Precellys CK14 lysing
tubes (Berlin Technologies) in a FastPrep-24 tissue homogenizer (MP Biomedicals) with three
30 s cycles. Crude lysates were centrifuged three consecutive times for 10 min at 16,000 rcf and
4˚C, and the supernatant was transferred to a new tube after each centrifugation step. For all
tissue homogenates, the total protein concentration was determined using the bicinchoninic
acid assay (BCA; Thermo Scientific) and adjusted to 1.5, 2, or 5 mg/mL with tissue lysis buffer.
Homogenates were aliquoted, snap-frozen, and stored at -80˚C.
Size-exclusion chromatography (SEC)
500 μL of 3–5 mg/mL whole brain homogenates from a heterozygous zQ175 (age: 14 months)
or R6/2 mouse (age: 12 weeks) were fractionated by SEC on a Superose 6 10/300 GL column
(GE Healthcare Life Sciences). For calibration of the column, 500 μL of 5 fmol/μL full-length
HTT-Q17 and Q46, 25 fmol/μL of MBP-tagged HTT(1–97)-Q46, and 200 fmol/μL thrombin-
digested HTT(1–97)-Q46 were included. All SEC experiments were performed in SEC buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100) at 4˚C with
a flow rate of 0.5 mL/min, and elution of 1.2 column volume. Fractions (300 μL volume/frac-
tion) were collected in a 96-well plate and diluted 1:1 in blocking buffer (2% probumin/0.2%
Tween-20 in PBS) for MSD analysis.
MSD assays
MSD 384-well plates (Meso Scale Discovery) were coated overnight at 4˚C with 10 μL of coat-
ing antibody in a carbonate-bicarbonate coating buffer (15 mM Na2CO3/35 mM NaHCO3, pH
9.6) per well. Plates were then washed three times with 35 μL of wash buffer (0.2% Tween-20
in PBS) per well and blocked with 35 μL of blocking buffer (2% probumin/0.2% Tween-20 in
PBS) per well for 1 h at RT with rotational shaking. Recombinant proteins or brain extracts
were diluted to the desired concentrations in a mixture of aggregation buffer or tissue lysis
buffer and at least 50% blocking buffer. For spike recovery experiments, recombinant protein
samples were spiked into 1 mg/mL of a wildtype zQ175 mouse whole brain lysate. After an
additional washing step, 10 μL per sample was transferred to each well of the antibody-coated
MSD plate and incubated with shaking for 1 h at RT. After disposal of samples and four wash
cycles with 35 μL of wash buffer each, 10 μL of the primary detection antibody (SULFO-TAG
(ST) labeled or non-labeled) was added to each well and incubated with shaking for 1 h at RT.
For non-labelled primary detection antibodies, 10 μL goat anti-mouse SULFO-TAG labeled
secondary detection antibodies (1:1,000 in blocking buffer; Meso Scale Discovery) was added
to each well after an additional washing step and incubated with shaking for 1 h at RT. After
washing three times with wash buffer, 35 μL of read buffer T with surfactant (Meso Scale Dis-
covery) was added to each well and the plate was imaged on a Sector Imager 6000 (Meso Scale
Discovery) according to manufacturers’ instructions. The following antibody combinations
were used: 4 μg/mL pAb147 (coating) / 1:1,000 MAB2166 (detection) / 1:1,000 anti-mouse-ST
(secondary detection); 5 μ = g/mL 2B7 / 0.1 μg/mL 4C9-ST; 5 μg/mL 2B7 / 5 μg/mL MW1-ST;
4 μg/mL MW8 / 1 μg/mL 4C9-ST; 2 μg/mL MW8 / 5 μg/mL MW8-ST. Optimal antibody con-
centrations may vary with each new ST-labelled antibody batch.
TR-FRET assays
The samples tested in the MSD assays were also applied for TR-FRET analysis. 5 μL per sample
in tissue lysis buffer and at least 50% blocking buffer was transferred to a low-volume 384-well
plate (Greiner), followed by addition of 1 μL of antibody mix in 50 mM NaH2PO4, 400 mM
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NaF, 0.1% BSA, 0.05% Tween20 and incubation for 1 h at RT. Samples were measured using
an EnVision plate reader (PerkinElmer) with excitation at 320 nm and readout at 615 nm and
665 nm (d2) or 530 nm (AlexaFluor 488), respectively. Used antibody combinations and final
amounts per well comprise: 0.25 ng 2B7-Tb / 20 ng MW1-d2; 1 ng 4C9-Tb / 10 ng 4C9-Alexa-
Fluor 488 (AF488); 1 ng MW8-Tb / 10 ng MW8-d2. Antibody labeling with Tb, d2, or AF488
was performed by Cisbio Bioassays (Codelet, France).
Seprion ELISA
2.5% w/v lysates were prepared in RIPA buffer (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 1%
Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM β-mercaptoethanol, 1 mM PMSF,
0.5 mM DTT, and mini-protease inhibitor cocktail (Roche Diagnostics)) by ribolysing in lysis
matrix D tubes (MP Biomedicals) 2 times for 30 s at 4˚C, transferred to ice for 5 min for cool-
ing before the third 30 s ribolysation step. Lysates were centrifuged at 13,000 rpm for 2 min.
Supernatants were used immediately or snap-frozen on dry ice and stored at -80˚C. 15 μL of
the 2.5% ribolysate was mixed with 3 μL 10% SDS, 62 μL water and 20 μL of 5x Microsens cap-
ture buffer in PCR tubes. The sample was transferred to a Seprion ELISA plate (cat# SEP1-96-
01; Microsens Biotechnologies) and incubated for 1 h at 23˚C in a plate shaker. Wells were
washed 5 times with 0.1% PBS-T (PBS / 0.1% Tween-20) and any residual buffer was removed.
100 μL of the primary antibodies S830 or MW8 were added at 1:2,000 dilution in conjugate
buffer (150 mM NaCl, 4% BSA (98% electrophoretic grade), 0.1% Tween 20, 1% skimmed
milk powder) and incubated at 23˚C for 1 h. The washing step with PBS-T was repeated 5
times, followed by incubation with 100 μL of an HRP-conjugated anti-sheep (Abcam) or anti-
mouse secondary antibody (ThermoFisher) at 1:2,000 dilution in conjugate buffer for 45 min
at 23˚C. The washing step with PBS-T was repeated 5 times and 100 μL TMB substrate
(warmed to 23˚C) was added. The reaction was stopped with 100 μL of 0.5 M HCl when the
required saturation was reached, and absorption was read at 450 nm using a Bio-Rad plate
reader.
Results
Detection of recombinant HTT aggregates
The MW8 antibody, known to bind aggregated HTT [24], was used in the development of the
MSD-based HTT aggregate assays. As a suitable standard protein, a maltose binding protein
(MBP)-tagged human HTT fragment (aa 1–97 to include the MW8 epitope and a short spacer
before the C-terminal His6 tag) with a polyQ stretch of 46 glutamines (HTT(1–97)-Q46) was
generated. The MBP-tag was incorporated to maintain the protein in a soluble monomeric
state. Thrombin protease-cleavage of the MBP-tag and incubation at 37˚C induces aggregation
[36]. First, we compared concentration response curves for HTT(1–97)-Q46 before and after
24 h of aggregation. In these experiments, an equivalent HTT(1–97)-Q16 control protein con-
taining a non-pathogenic polyglutamine domain was included which does not form aggregates
after protease digestion in comparison to the mutant HTT fragment. We confirmed almost
complete cleavage of the MBP-tag after 24 hours incubation with the protease by western blot-
ting for both constructs. In addition, the observed band for HTT(1–97)-Q46 was less promi-
nent than the one for HTT(1–97)-Q16, reflecting the incorporation of digested HTT(1–97)-
Q46 into larger aggregates detected at a higher molecular weight band (S1 Fig).
The MBP-tagged and thrombin-digested HTT(1–97)-Q16 and HTT(1–97)-Q46 were first
analyzed in the 2B7 / MW1-ST and 2B7 / 4C9-ST assays (S2 Fig). Because the 2B7 / MW1-ST
assay is selective for polyQ expanded monomeric human HTT, no to minimal signal was
detected for HTT(1–97)-Q16, while detection of HTT(1–97)-Q46 was significantly reduced
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after thrombin digestion (Fig 1A). Analysis of the MBP-tagged HTT(1–97) constructs in the
2B7 / 4C9-ST assay for total, polyQ-independent, monomeric human HTT showed similar
results to those obtained with the 2B7 / MW1-ST assay: detection of HTT(1–97)-Q46 was
strongly reduced after cleavage of the MBP-tag. A small reduction in detection was also
observed for HTT(1–97)-Q16 (Fig 1B). In summary, the results indicate that detection of HTT
(1–97)-Q46 monomer levels was reduced due to aggregation after cleavage of the MBP-tag.
Signal detection in the thrombin-digested samples was still noticeable, likely due to epitope
availability on the aggregate surface. However, the shift in the response curve for digested
HTT(1–97)-Q16 in the 2B7 / 4C9-ST assay could also reflect an oligomerization or aggregation
process of the shorter polyQ domain, indicating that incubation at high concentrations for 24
h at 37˚C had induced oligomerization of HTT(1–97)-Q16 [37].
For the development of potential aggregation assays, multiple combinations of MW8 with
other anti-HTT antibodies were tested for their ability to detect a signal increase after protease
digest and subsequent incubation. MW8 was evaluated as a capture antibody, as well as a
detection antibody. Best results were obtained for the following antibody combinations:
Fig 1. Monomer and aggregate assays for analysis of HTT(1–97)-Q16 and Q46. MBP-tagged and thrombin-digested human HTT(1–97)-Q16 and Q46 were
tested after 24 h incubation at different concentrations in the monomer assays: 2B7 / MW1-ST (A) and 2B7 / 4C9-ST (B), and the aggregate assays: MW8 /
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MW8 / 4C9-ST and MW8 / MW8-ST. Both putative MSD aggregate assays showed the stron-
gest signal response for aggregated HTT(1–97)-Q46 (Fig 1C and 1D) with a lower limit of
detection (LLOD) of approximately 10 pM and a linear range across at least 4 log units
(Table 1). Importantly, both MBP-tagged monomeric HTT(1–97) constructs and thrombin-
digested HTT(1–97)-Q16 were detected to a significantly lower extent, with LLODs for these
constructs being at least 100-fold higher than for aggregated HTT(1–97)-Q46 (Table 1).
In summary, assays 2B7 / MW1-ST and 2B7 / 4C9-ST showed a clear preference for detec-
tion of HTT monomers (Fig 1A and 1B), whereas assays MW8 / 4C9-ST and MW8 / MW8-ST
preferentially detected HTT protein at higher aggregation states (Fig 1C and 1D). Detection of
aggregated HTT(1–97)-Q46 was also confirmed by immunoprecipitation with MW8 (S3 Fig).
However, our data also suggests that the first two assays detected aggregated HTT to some
extent, while the latter ones also showed detection of a weaker signal response for non-aggre-
gated HTT. Nonetheless, to facilitate matters, we will refer to assays 2B7 / 4C9-ST and 2B7 /
MW1-ST as “monomer assays” and to assays MW8 / 4C9-ST and MW8 / MW8-ST as “aggre-
gate assays” herein.
When monitoring aggregation kinetics, a gradual signal increase was observed over time
with a plateau after approximately 8 h for the antibody combinations MW8 / 4C9-ST and
MW8 / MW8-ST (Fig 2). Aggregation kinetics using the MW8 antibody were also confirmed
by an orthogonal filter retardation assay (S4 Fig). Simultaneously, a time-dependent signal
decrease was measured in the MSD assays 2B7 / 4C9-ST for total human HTT and 2B7 /
MW1-ST for human mHTT (Fig 2).
It has been previously shown that the peptide QBP1 is capable of preventing proteins with
polyQ stretches from aggregating [30, 31]. We therefore performed a thrombin-digest with
subsequent incubation for 24 h at 37˚C in the presence of Antp-QBP1, with negative controls
Antp-scrQBP1 and Antp, to see if treatment reduced the signals detected for aggregated HTT
(1–97)-Q46 by blocking aggregate formation. As detected in the MW8 / 4C9-ST (Fig 3A) and
MW8 / MW8-ST (Fig 3B) assays, Antp-QBP1 indeed inhibited aggregation with apparent IC50
values of 28.7 μM (MW8 / 4C9-ST) and 24.8 μM (MW8 / MW8-ST). The Antp-scrQBP1
showed a minor inhibitory effect but only at IC50 values above the highest tested peptide con-
centration of 100 μM. Antp did not show any inhibitory effect. These data are consistent with
the HTT proteins being in an aggregated state in the two assays.
To demonstrate that the newly developed assays specifically detect HTT aggregate confor-
mations, we examined whether the assays could detect amyloid aggregates as found in the
brain of Alzheimer’s patients [38]. Amyloid- β (Aβ) fibrils were generated from Aβ42 peptides











0.8 nM 19 nM - -
LLOD; Digested HTT(1–97)-Q16 1.3 nM 2.7 nM - -
LLOD; MBP-HTT(1–97)-Q46 0.9 nM 1.8 nM - -
LLOD; Digested HTT(1–97)-Q46 8 pM 18 pM 38 nM 18 nM
Fold difference of LLOD; HTT(1–97)-Q46 before and after thrombin digest ~ 100x ~ 100x - -
Fold difference of LLOD; HTT(1–97)-Q16 and Q46 after thrombin digest ~ 150x ~ 150x
Dynamic range (log units) ~ 4 ~ 4.5 ~ 2 ~ 2
Lower limit of detection (LLOD) was determined using the Discovery Workbench 4.0 software (Meso Scale Discovery) using the mean of the background plus 2.5 times
the standard deviation. Log units were defined by visual evaluation.
https://doi.org/10.1371/journal.pone.0213521.t001
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in vitro and aggregation was confirmed by Thioflavin T assay (S5A Fig). Analysis of Aβ fibrils
in the assays MW8 / 4C9-ST and MW8 / MW8-ST resulted in an absence of signal detection
(S5B and S5C Fig). This indicates that the two HTT aggregate assays are not general pan-
aggregate assays as they show selectivity for HTT aggregates when compared to Aβ fibrils gen-
erated in vitro.
In addition to HD there are other CAG repeat disorders such as Machado-Joseph Disease
(MJD), also known as spinocerebellar ataxia type 3 (SCA3). In MJD, the disease is caused by
an abnormal CAG expansion in the gene for ATXN3 [39]. We therefore tested our assays to
see if they would detect any polyQ-dependent aggregates independent of the surrounding
sequences. To this end, we used a GST-tagged polyQ46 protein which was aggregated after
thrombin-cleavage of the GST-tag. PolyQ46 aggregation was confirmed by Thioflavin T assay
(S5D Fig). In the following MSD analysis, no signals were detected for aggregated polyQ46 in
both the MW8 / 4C9-ST or the MW8 / MW8-ST assays (S5E and S5F Fig). This data demon-
strates that our assays do not detect any polyQ aggregate but rather are specific for aggregated
mHTT.
Before applying the novel HTT aggregate assays to the analysis of tissue samples, the recov-
ery rate for spiked aggregated HTT(1–97)-Q46 standard curves in 1 mg/mL whole brain lysate
from wild type mice were measured. None of the assays were significantly affected by the tissue
matrix (S6 Fig).
Fig 2. Aggregation kinetics of HTT(1–97)-Q46. Aggregation of HTT(1–97)-Q46 was initiated by addition of thrombin protease, followed by incubation for 24 h
at 37˚C. Samples were taken at the given time points and analyzed at 1 nM in the 2B7 / 4C9-ST and 2B7 / MW1-ST assays for monomeric human HTT or human
mHTT, respectively. Additionally, samples were measured at 1 μM in the MW8 / 4C9-ST and MW8 / MW8-ST aggregate assays. Data were normalized: signal at 0
h was set to 100% for both 2B7 assays; signal at 24 h was set to 100% for both MW8 assays. Results were confirmed in three independent runs with one
representative dataset shown. Error bars represent standard deviation for three technical replicates. In some cases, error bars are too small to be visible.
https://doi.org/10.1371/journal.pone.0213521.g002
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Detection of native aggregates from HD mouse models
Following identification of putative HTT MSD assays to detect recombinant HTT aggregates,
we next tested these assays for detection of age-dependent native HTT aggregates formed in
the brain of three different HD mouse models. It has been previously shown by immunohis-
tochemistry (IHC) that the amount of HTT aggregates increases with age in R6/2 [19, 22],
zQ175 [13], and BACHD [26] mice. In general, endogenous mouse HTT levels determined in
the pAb147 / 2166 / anti-mouse-ST assay [19] were constant across different ages and between
wild type and respective HD animals for R6/2 and BACHD mice (S7A and S7C Fig). However,
while analysis of whole brain lysates from 3 and 14 month-old heterozygous Q175 (hetQ175)
mice showed comparable levels of mouse HTT, it is noted that WT mice showed approxi-
mately double the signal intensity due to the human sequence knock-in construct of the
hetQ175 animals not being detected by the mouse MSD assay (S7B Fig). Signals detected by
the mHTT-specific 2B7 / MW1-ST assay decreased with age in all three HD models, poten-
tially due to the loss of monomeric mHTT by incorporation into aggregates (Fig 4A–4C). Vice
versa, analysis of tissue homogenates in the two aggregate assays, MW8 / 4C9-ST and MW8 /
MW8-ST, showed an age-dependent increase in assay signals (Fig 4D–4I). Strongest signals
were detected in R6/2 animals, followed by hetQ175 mice. Signals were observed to be low for
BACHD animals in the MW8 / 4C9-ST assay (Fig 4F) and below the limit of detection in the
MW8 / MW8-ST assay (Fig 4I). These results could potentially reflect the aggregate load in the
various HD mouse models. The exon 1 construct in R6/2 animals shows the strongest ten-
dency for aggregation. The full-length HTT construct with humanized exon 1 (~190Q) in
zQ175 mice (or more likely an exon1 HTT protein generated through incomplete splicing of
the full-length HTT sequence [40]) shows a significant level of aggregation, but clearly to a
lower extent in comparison to R6/2 animals. Only a small amount of aggregates can be
detected for human full-length HTT (97Q) in the BACHD mice, concomitant with the smallest
age-dependent decrease of soluble mHTT levels of all three models (Fig 4C). Overall, the MSD
data for the HD mouse model age series confirms the previously published IHC data, and
therefore supports the preferential detection of aggregates in the newly developed MSD assays.
Fig 3. Inhibition of aggregation. Protease-cleavage and subsequent aggregation of 33 μM MBP-HTT(1–97)-Q46 were performed in presence of a concentration
series of peptides Antennapedia (Antp), Antp-QBP1, and Antp-scrQBP1. After aggregation, samples were diluted to 250 nM HTT(1–97)-Q46 and analyzed in the
MW8 / 4C9-ST (A) and MW8 / MW8-ST assays (B). Error bars represent standard deviation for three independent measurements.
https://doi.org/10.1371/journal.pone.0213521.g003
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As shown in Fig 4 and S6 Fig, multiple HTT species are present in brain tissue homogenates
from HD mouse models: endogenous non-expanded mouse HTT, genetically introduced
human exon 1 or full-length mHTT, and HTT aggregates. To confirm that the newly devel-
oped assays were selective for aggregate species present in these samples, whole brain homoge-
nates from a 12 week-old R6/2 and a 14 month-old hetQ175 mouse were separated on a
Superose 6 size-exclusion chromatography (SEC) column followed by analysis of each elution
fraction. In this procedure, proteins are separated by size, with the larger size proteins found
in the earlier elution fractions.
Fig 4. Analysis of human mHTT and HTT aggregates in an age series of HD mouse models. Whole brain lysates of an age series of R6/2 (left), hetQ175 (middle),
and BACHD (right) mice were analyzed at 0.5 mg/mL (R6/2 and hetQ175), 0.1 mg/mL (BACHD, mHTT), and 2.5 mg/mL (BACHD, aggregates) in the 2B7 /
MW1-ST (A-C) assay for human mHTT and the MW8 / 4C9-ST (D-F) and MW8 / MW8-ST (G-I) assay for aggregated HTT. Background: signal generated by
sample buffer. Error bars represent standard deviations of at least three biological replicates. Samples were compared based on a one-way ANOVA statistical analysis:
� p< 0.05, �� p< 0.01, ��� p< 0.001, ���� p< 0.0001, n.s. not significant. # below limit of detection.
https://doi.org/10.1371/journal.pone.0213521.g004
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The SEC column was initially calibrated using several recombinant HTT proteins: MBP-
tagged monomeric HTT(1–97)-Q46 (Mw: 58 kDa), thrombin-digested, aggregated HTT(1–
97)-Q46, human full-length HTT-Q17 (Mw: 347 kDa) and Q46 (Mw: 351 kDa). The main elu-
tion peak for HTT(1–97)-Q46 monomers was detected at 16 mL (S8A Fig), while the aggre-
gated HTT(1–97)-Q46 eluted at approximately 8 mL (S8B Fig). Both full-length HTT-Q17 and
Q46 eluted at 11–12 mL (S8C and S8D Fig). Elution peaks in the tissue homogenate samples
were identified by comparison to these standard peaks.
The elution profile obtained for the R6/2 whole brain lysate (Fig 5A) showed one single
peak in the 2B7 / MW1-ST monomer assay at 16 mL of elution, reflecting monomeric exon 1.
In the putative aggregate-selective MW8 / 4C9-ST and MW8 / MW8-ST assays, the major sig-
nal was detected at 8 mL of elution, corresponding to that of recombinant HTT(1–97)-Q46
aggregates. The potential aggregate elution peaks in both assays were relatively broad. The cor-
responding size of the HTT species detected in these fractions was larger than the expanded
exon 1 monomer expressed in R6/2 mice, and could therefore represent a wide range of aggre-
gate sizes.
The elution profile of the hetQ175 whole brain lysate (Fig 5B) showed one single peak at 8
mL of elution in the MW8 / 4C9-ST and MW8 / MW8-ST assays, also in line with the recom-
binant aggregate standard, and showing a comparable profile to that detected in the R6/2
mice. Two elution peaks were observed in the 2B7 / MW1-ST monomer assay: a larger elution
peak at 12 mL and a smaller peak at 16 mL. HetQ175 mice express full-length mHTT reflected
by the larger peak at 12 mL. Comparison with the elution profile of an MPB-HTT(1–97)-Q46
standard (S8A Fig) suggests that the minor peak detected at 16 mL most likely represents
monomeric exon 1 HTT, or potentially also smaller N-terminal mHTT fragments that cannot
be resolved by the applied SEC method. It has previously been shown that in zQ175 mice, and
other knock-in models, exon 1 does not always splice to exon 2, thereby generating a small
polyadenylated mRNA that encodes the mutant exon 1 HTT protein [40]. The amount of solu-
ble exon 1 HTT decreases in zQ175 brains with disease progression [41]. In summary, elution
peaks containing the major signal for aggregated HTT were observed for both mouse models
by both aggregate assays, and were in accordance with peaks observed for recombinant HTT
Fig 5. Analysis of R6/2 and zQ175 whole brain lysates after SEC. Whole brain homogenates from (A) a 12 week-old R6/2 (500 μL at 3 mg/mL) and (B) a 14
month-old hetQ175 mouse (500 μL at 5 mg/mL) were run on a Superose 6 SEC column. Elution fractions were subsequently analyzed in the 2B7 / MW1-ST assay
for human mHTT and the aggregate assays MW8 / 4C9-ST and MW8 / MW8-ST. Background: signal generated by sample buffer. Curve shapes were smoothed.
Confirmation of detected HTT species by Western blotting of individual elution fractions failed as samples were too dilute after SEC.
https://doi.org/10.1371/journal.pone.0213521.g005
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samples. Overall, analysis of lysates from HD model mouse brains after SEC supported the
detection of HTT aggregates in both assays.
We next examined the ability of the MSD assays to detect changes in HTT aggregate levels
in brain tissue following zinc-finger mediated repression of mutant Htt gene expression. In
brief, a transcription repressor protein was directed via a zinc-finger domain to the CAG tract
of the Htt gene. The zinc-finger domain was designed to specifically target the mutant form of
the gene. Subsequently transcription of mHTT was blocked. Due to a marked reduction in the
level of polyQ-expanded HTT monomers, ZFP treatment leads to a subsequent reduction in
HTT aggregate formation [14, 15]. Based on these observations, intra-striatal injection of AAV
particles carrying either a FLAG-tagged ZFP construct (AAV-ZFP-30640; S9A Fig) or a nega-
tive control ZFP construct lacking the DNA-binding domain (AAV-ZFP-ΔDBD; S9B Fig) was
performed in two month-old hetQ175 mice. Four months after treatment, mice were sacrificed
and brain tissue was collected. IHC analysis of whole brain sections from treated mice was per-
formed with an anti-FLAG antibody. Results indicated that the AAV injection transduced
more than 50% of the striatum (S9C and S9D Fig). In AAV-ZFP-ΔDBD treated animals, HTT
aggregates detected with the EM48 antibody were abundant throughout the striatum. In con-
trast, aggregate levels were reduced by more than 90% in FLAG-positive medium spiny neu-
rons of AAV-ZFP-30640 treated mice (S9C–S9F Fig). For subsequent testing in the aggregate-
selective MSD assays, striata from AAV-ZFP-30640 and AAV-ZFP-ΔDBD treated animals, as
well as untreated control mice, were dissected and homogenized. Analysis of striatal lysates in
both the 2B7 / 4C9-ST assay for total monomeric human HTT and the MW8 / 4C9-ST and
MW8 / MW8-ST aggregate assays showed a 30–50% reduction in HTT levels in AAV-ZFP-
30640 treated samples compared to AAV-ZFP-ΔDBD and untreated samples (Fig 6). Quantifi-
cation of HTT aggregate levels showed comparable results for both aggregate assays, with levels
around 15,000–20,000 fmol/mg for the untreated and AAV-ZFP-ΔDBD samples. While data
from the MSD assays confirmed the IHC results, the calculated 30–50% reduction in HTT
aggregates was significantly lower than the 90% reduction of both nuclear and perinuclear
aggregates observed by IHC. This difference can be explained by the fact that only AAV-
infected medium spiny neurons were evaluated in the IHC analysis, while the whole striatum,
including non AAV-transduced areas, was used for analysis in the MSD assays.
Fig 6. MSD analysis of AAV-ZFP-treated zQ175 mice showed reduction of mutant HTT and HTT aggregate levels. Quantification of human mHTT (A) or
HTT aggregates (B and C). Analysis of striatal tissues from untreated hetQ175 mice, animals injected with AAV-SWB-ZFP-ΔDBD, or AAV-SWB-ZFP30640.
Error bars represent standard deviation for analysis of at least 20 samples. n.s. not significant, ���� p< 0.0001.
https://doi.org/10.1371/journal.pone.0213521.g006
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Comparison with existing assay technologies
Two different assay systems have been previously described for the detection of HTT aggre-
gates: 1) TR-FRET assay with the antibody combinations 4C9-Tb / 4C9-AF488 and MW8-Tb /
MW8-d2 [23]; and 2) Seprion ELISA [22] using a proprietary aggregate-binding ligand. We
next compared data generated by the newly-developed MSD assays with these existing assay
technologies. For comparison to the TR-FRET assays, experiments with recombinant HTT(1–
97) were performed, including aggregation kinetics and analysis of HTT(1–97)-Q16 and Q46
before and after thrombin-digestion. Similar to the results from the MSD assays (Fig 2), a grad-
ual signal increase over time was observed, with a signal plateau after approximately 8 h incu-
bation (Fig 7A). The 4C9-Tb / 4C9-AF488 assay also detected uncleaved MBP-HTT(1–97)-
Q46 to some extent, and showed a signal response at the earliest time points (Fig 7A). These
data suggest that this assay can already detect smaller HTT oligomers. When comparing detec-
tion of MBP-tagged and cleaved HTT(1–97)-Q16 and HTT(1–97)-Q46, the MW8-Tb /
MW8-d2 TR-FRET assay showed preferential detection of aggregated HTT(1–97)-Q46 (Fig
7B). The 4C9-Tb / 4C9-AF488 assay also showed a strong signal response for aggregated HTT
(1–97)-Q46; however, a signal response was also observed for digested HTT(1–97)-Q16 (Fig
7C). These data suggest that the 4C9-Tb / 4C9-AF488 TR-FRET assay might also detect oligo-
mers or smaller aggregate species formed by thrombin-digested HTT(1–97)-Q16 [37], which
is in accordance with results observed for the aggregation kinetics (Fig 7A). Overall, the limits
of detection of 38 nM for the MW8-Tb / MW8-d2 and of 18 nM for the 4C9-Tb / 4C9-AF488
assays were more than 1000-fold higher than those determined for the MSD aggregate assays
(Table 1).
For comparison of the HTT aggregate MSD assays to the Seprion ELISA, the cortex, two
striata, and two musculus tibialis anterior were collected from R6/2 and wild type mice at 4, 8,
and 14 weeks of age. Half a cortex, one striatum and one TA was used from each mouse in the
MSD aggregation and Seprion ELISA assays according to the standard protocols for each tech-
nique. As previously described, the amount of HTT aggregates in the brain increased with age
(Fig 4D and 4G; [22]). Both MSD and Seprion ELISA assays showed comparable results for
the cortex and striatum samples, with a similar age-dependent signal increase (Fig 8A and 8B).
While the age-effect was also confirmed in the TA samples for both assay formats, detection of
HTT aggregates in the TA samples appeared to be more sensitive in the MSD assays, where sig-
nals were detected as early as 4 weeks of age (Fig 8C). In summary, the newly developed assays
described here show comparable results to already published HTT aggregate-selective assays,
displaying equal or improved assay performance.
Discussion
The evaluation of current HTT-lowering approaches for treatment of HD requires the avail-
ability of assays that are capable of measuring HTT levels in relevant HD model or patient
samples. Multiple assay technologies are available to measure different monomeric HTT spe-
cies [16–18, 20]. For example, MSD assays have been described for detection of mouse HTT,
human HTT or mutant HTT [19]. Besides the presence of the pathogenic monomeric mHTT
protein, aggregation of HTT protein is another hallmark of HD. However, only very few assays
have been described that specifically target HTT aggregates [22, 23]. To complement the avail-
able set of MSD assays for detection of different HTT species, we developed two assays that
preferentially detect aggregated HTT. The described MW8 / 4C9-ST and MW8 / MW8-ST
MSD assays were evaluated using both recombinant HTT proteins and different tissue samples
from HD mouse models. Each of the performed tests showed a distinct detection pattern in
comparison to MSD monomer assays and confirmed that the two novel assays are
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preferentially detecting HTT in an aggregated form. Both assays show similar overall perfor-
mance, with the MW8 / 4C9-ST assay being slightly more sensitive. When set against existing
HTT aggregate assays, our assays showed comparable results with equal or improved assay
performance. The novel MSD assays are clearly more sensitive in the detection of HTT aggre-
gates in comparison to existing TR-FRET assays with more than 1000-fold lower LLODs. The
Seprion ELISA is carried out in 96-well format. The described MSD assays are run in 384-well
format and therefore allow for a higher throughput. Seprion ligands have been described to
Fig 7. Analysis of HTT(1–97)-Q16 and Q46 by TR-FRET. (A) Aggregation kinetics of HTT(1–97)-Q46. Aggregation of HTT(1–97)-Q46 was initiated by
addition of thrombin protease, followed by incubation for 24 h at 37˚C. Samples were taken at the given time points and analyzed at 1 nM in the 2B7-Tb /
MW1-d2 TR-FRET assay for human mHTT. Additionally, samples were measured at 1 μM in the MW8-Tb / MW8-d2 and 4C9-Tb / 4C9-AF488 TR-FRET assays
for HTT aggregates. Data was normalized: signal at 0 h was set to 100% for the 2B7-Tb / MW1-d2 assay; signal at 24 h was set to 100% for the MW8-Tb / MW8-d2
and 4C9-Tb / 4C9-AF488 assays. Results were confirmed in three independent runs with one representative dataset shown. Error bars represent standard
deviation for three technical replicates. (B) and (C) Analysis of MBP-tagged and thrombin-digested human HTT 1–97 Q16 and Q46 at different concentrations in
the MW8-Tb / MW8-d2 (B) and 4C9-Tb / 4C9-AF488 (C) TR-FRET aggregate assays. Error bars represent standard deviation for three independent
measurements. In some cases, error bars are too small to be visible.
https://doi.org/10.1371/journal.pone.0213521.g007
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also detect non-HTT aggregates like prions and amyloid-β [42, 43]. Our data suggest that the
two novel MSD assays described here do not detect other protein oligomeric or aggregated
species, such as Aβ fibrils (S5 Fig) for which no signals were detected. Lastly, for the analysis of
musculus tibialis anterior samples the MSD assays showed improved sensitivities (Fig 8C).
Both assays are based on the MW8 antibody, which has previously been shown to recognize
HTT aggregates in IHC applications [24, 25]. EM48, a mouse monoclonal antibody raised
against a GST fusion protein including the first 256 amino acids of human HTT, was also
shown to label HTT aggregates in IHC studies [13, 44]. The EM48 antibody (MAB5374; Milli-
pore) was also evaluated in the course of this study. Data generated for the analysis of recombi-
nant HTT proteins with antibody combinations including EM48 also suggested potential
aggregate-binding. However, assay signals were strongly suppressed by a mouse brain tissue
matrix, which lead to signal intensities for aggregated HTT in mouse model tissues only mini-
mally above or below the LLOD. Therefore, the EM48 antibody was not used for further evalu-
ation. The epitope sequence for the MW8 antibody is not only present on aggregates, but also
on monomeric HTT. It has been shown that MW8 is a neo-epitope antibody for the C-termi-
nus of exon 1 HTT, that it does not detect this sequence when present in a longer HTT frag-
ment or the full-length protein, and that its’ recognition of this epitope is dependent on the
presence of the C-terminal proline [45]. Whilst the MW8 / MW8-ST assay might be expected
to detect oligomers / aggregates, it is not clear as to why the MW8 / 4C9-ST combination is
specific to HTT aggregates, given that MW8 can detect soluble exon 1 HTT [40, 45].
Fig 8. Comparison of MSD assays and Seprion ELISA. Homogenates of (A) cortex, (B) striatum, and (C) musculus tibialis anterior tissues of an aged series of R6/2
mice were analyzed at 1 mg/mL (cortex, TA) or 0.75 mg/mL (striatum) in the MW8 / 4C9-ST and MW8 / MW8-ST MSD assays, or using 15 μL of a 2.5% (w/v)
ribolysate in the Seprion ELISA assay utilizing antibodies S830 or MW8. The background signal in the Seprion ELISA samples is generated by the substrate (see WT
samples). Error bars represent standard deviations of four (WT) or eight (R6/2) biological replicates.
https://doi.org/10.1371/journal.pone.0213521.g008
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One aspect of the described assays that has not yet been addressed is which types of aggre-
gates are being detected. In general, the term aggregate is a term that encompasses oligomers,
protofibrils, fibrils and inclusions. Considering the data for the aggregation kinetics of HTT
(1–97)-Q46 (Fig 2), and the elution profiles for analysis of R6/2 and zQ175 mouse whole brain
lysates after SEC (Fig 5), both the MW8 / 4C9-ST and the MW8 / MW8-ST assay seem to a
wide range of aggregate species. Comparison of these elution profiles to elution peaks obtained
for a reference protein calibration mix indicated that the molecular weight of molecules eluting
at 8 mL is larger than 700 kDa and most probably in the MDa range (molecules detected at 8
mL eluted earlier than a thyroglobulin calibration standard with a molecular weight of 669
kDa).
The principle of TR-FRET is a detectable energy transfer between two labeled antibodies
bound in close proximity. This means that the applied TR-FRET assays can potentially already
detect HTT dimers and smaller oligomers. In particular, the 4C9-Tb / 4C9-AF488 assay
seemed to detect smaller HTT oligomers or aggregates, as seen by the signal increase at the
very early time points of aggregation (Fig 7A) and a significant signal for the detection of
thrombin-digested HTT(1–97)-Q16 (Fig 7C). These potentially smaller species detected by the
4C9-Tb / 4C9-AF488 TR-FRET assays are not identified in our MSD aggregate assays, which
means that a certain aggregate size is required for detection. To determine and characterize
the type of aggregates detected by our assays, the in vitro generated HTT(1–97)-Q46 aggregates
could be analyzed by electron microscopy (EM) or atomic force microscopy (AFM).
Tissue homogenates of R6/2, zQ175, and BACHD mouse models were analyzed during the
course of this study. These HD model animals differ in the expressed mHTT species and Q-
length. R6/2 animals are transgenic for the 5’ region of the human HTT gene that contains
exon 1 with approximate Q-lengths of 120 [33] in the colony maintained at the Jackson Labo-
ratory, and 210 in the colony maintained by the Bates Lab. zQ175 mice produce a chimeric
full-length HTT in which exon 1 of mouse HTT is replaced by the human sequence with an
average Q-length of around 198 [35]. zQ175 mice also express exon 1 HTT encoded by a small
polyadenylated mRNA that is generated through incomplete splicing [40]. Our size-exclusion
chromatography data revealed a peak at 16 mL of elution consistent with the presence of the
exon 1 HTT monomer. BACHD mice express a human full-length HTT with Q-length of 97
[26]. Analysis of the age series for each of these three mouse models in our aggregate assays
suggests that formation of aggregates is dependent on overall construct length and polyQ-
length. The highest signals were detected in the R6/2 mice (Fig 4D and 4G), as exon 1 HTT
aggregates very readily. Aggregate-levels in the oldest animals were approximately 5-10-fold
lower in hetQ175 animals in comparison to R6/2 mice (Fig 4E and 4H), which may be consis-
tent with the lower level of exon 1 HTT present in these knock-in mice. The lowest signals
were measured in the BACHD mice. Here, considering the applied total lysate concentrations,
signals for the oldest animals were around 100-fold lower than for the hetQ175 animals in the
MW8 / 4C9-ST assay (Fig 4F). In the MW8 / MW8-ST assays, signals were below the limit of
detection for all samples (Fig 4I). One reason for the differences in aggregate load between
hetQ175 and BACHD mice could be the significant longer Q-length in the hetQ175 animals.
For all three animal models, the observed increase in aggregate levels was stronger than the
concomitant decrease of mHTT levels (Fig 4A–4C). This could be due to the intracellular gen-
eration of new mHTT protein to compensate for the mHTT molecules that had been incorpo-
rated into aggregates and to retain a constant level of cellular monomeric HTT.
Following the analysis of tissue samples from HD mouse models, we also attempted to
detect HTT aggregates in cortical samples of human HD patients. Patients were heterozygous
with respect to expanded CAG repeats and the average Q-length was 45. However, no signals
above the LLOD could be detected in any of the samples for either the MW8 / 4C9-ST or the
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MW8 / MW8-ST assay. It has been recently shown that the amount of nuclear inclusions in neu-
rons of the prefrontal cortex is dramatically higher in HD mouse models (i.e. R6/2 and zQ175)
than in HD patient samples. While 40–50% of neurons in mouse models contained nuclear
mHTT inclusions, only 0.3% of neurons in human samples showed inclusions [46]. Therefore,
the relative aggregate load in the tested human samples was most certainly lower than for the
BACHD mouse homogenates. This means that the sensitivities of the presented assays are not
high enough to detect the very low abundant HTT aggregates in human patient samples. We
therefore would like to emphasize that we see the application of these assays in the analysis of
preclinical models of HD rather than for detection of HTT aggregates in human samples. Detec-
tion of human aggregates in the described MSD assays could possibly be achieved by an enrich-
ment step before analysis. Alternatively, the assays could be transferred to an antibody-based
method including an enrichment step, such as the Erenna Singulex technology.
In summary, we showed that the two newly developed assays preferentially detect HTT in
an aggregated form. These assays expand the capabilities of the available suite of MSD assays
for the identification and quantification of the different HTT species present in preclinical
models of HD. We recommend the presented assays for aggregated HTT to be used in parallel
with the soluble HTT assays to best assess the HTT protein population in particular biosamples
for HD model characterization and HTT lowering studies.
Supporting information
S1 Text. Supporting materials and methods.
(PDF)
S1 Fig. Western blot confirming aggregation of HTT(1–97)-Q46. Incubation of MBP-
tagged HTT(1–97)-Q16 or Q46 for 24 h at 37˚C in absence or presence of thrombin protease.
3 μg per sample were loaded onto the SDS-PAGE gel. After blotting, membranes were probed
with EM48 antibody and an alkaline phosphatase-conjugated secondary antibody. Western
blotting confirmed almost complete cleavage for both HTT(1–97) constructs, whereas high
molecular weight aggregates could only be observed for HTT(1–97)-Q46. Molecular weights:
MBP 43 kDa; MBP-HTT(1–97)-Q16: 54 kDa; MBP-HTT(1–97)-Q46: 58 kDa; thrombin-
digested HTT(1–97)-Q16: 11 kDa; non-aggregated thrombin-digested HTT(1–97)-Q46: 15
kDa. M: molecular weight marker. � This band is most probably an impurity from the purifica-
tion process. Please note: due to the unusual amino acid composition (high number of gluta-
mines), all bands are detected at a slight discrepancy to the molecular weight standard.
(TIF)
S2 Fig. Characterization of 2B7 / 4C9-ST and 2B7 / MW1-ST assays. Human N-terminal
HTT fragment 1–573 (HTT NF573)-Q23 and polyQ-expanded Q73 were tested at different
concentrations in the 2B7 / 4C9-ST and (B) 2B7 / MW1-ST assays. (A) While assay 2B7 /
MW1-ST is preferentially detecting mHTT, (B) assay 2B7 / 4C9-ST detects total soluble HTT
independent of Q-length. Error bars represent standard deviations for three independent mea-
surements. In some cases, error bars are too small to be visible.
(TIF)
S3 Fig. Immunoprecipitation of aggregated HTT(1–97)-Q46 with MW8. Monomeric and
thrombin-digested MBP-HTT(1–97)-Q46 were immunoprecipitated using the MW8 anti-
body. 0.2 μg of protein per lane were used as input control (lanes 1 and 2), while 2 μg of protein
were loaded for the immunoprecipitation with MW8 (lanes 3 and 4) and for the “beads only”
control (lanes 5 and 6). 4C9 was used as detection antibody. Detection of HTT aggregates by
MW8 was confirmed (lane 4), but also the monomeric HTT species MBP-HTT(1–97)-Q46
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(lane 3) and thrombin-digested non-aggregated HTT(1–97)-Q46 (lane 4) were immunopre-
cipitated by MW8 to some extent. Interpretation of results based on the cleaved, but non-
aggregated HTT(1–97)-Q46 bands (exon1-Q46) is not possible without doubt, as HTT(1–97)-
Q46 also binds unspecifically to the beads (lane 6). Considering that 10 times more material
was used for lanes 3 and 4 than for lanes 1 and 2, data suggests that almost all HTT aggregates
present in the input were pulled down by MW8, whereas only approximately 1% of MBP-HTT
(1–97)-Q46 (MBP-exon1-Q46) from the input were pulled down. Therefore, these data indi-
cate that MW8 is preferentially detecting aggregated HTT. Molecular weights: MBP-HTT(1–
97)-Q46: 58 kDa; non-aggregated thrombin-digested HTT(1–97)-Q46: 15 kDa. M: molecular
weight marker. � This band is most probably an impurity from the purification process. Please
note: due to the unusual amino acid composition (high number of glutamines), all bands are
detected at a slight discrepancy to the molecular weight standard.
(TIF)
S4 Fig. Filter retardation assay for measuring aggregation kinetics of HTT(1–97)-Q46.
Aggregation of HTT(1–97)-Q46 was initiated by addition of thrombin protease, followed by
incubation for 24 h at 37˚C. Samples were taken at the given time points and analyzed in a fil-
ter retardation assay using the MW8 antibody as primary detection antibody. (A) The stained
membrane showed a time-dependent MW8 signal increase after initiation of aggregation.
Non-digested monomeric MBP-HTT(1–97)-Q46 was not detected by MW8. (B) Quantifica-
tion of MW8 signals on the membrane confirmed the time-dependent signal increase with a
plateau being observed after 8 h of incubation. This result is in accordance with the MW8 /
4C9-ST and MW8 / MW8-ST MSD assay data. Error bars represent standard deviation for
technical duplicates. a.u. artificial units.
(TIF)
S5 Fig. Assay selectivity against amyloid-β fibrils and polyQ46 aggregates. (A) In vitro gen-
eration of Aβ 42 fibrils was confirmed by analysis of Aβ samples at different concentrations in
a Thioflavin T assay. The same fibrils were analyzed in the (B) MW8 / 4C9-ST and (C) MW8 /
MW8-ST MSD assays. Aggregated HTT(1–97)-Q46 was included as control. While both
assays showed a dose-dependent detection of aggregated HTT(1–97)-Q46, no signals were
observed for Aβ fibrils. D) In vitro generation of polyQ46 aggregates was confirmed by analysis
of GST-tagged and thrombin-cleaved polyQ46 at different concentrations in a Thioflavin T
assay. The same samples were analyzed in the (E) MW8 / 4C9-ST and (F) MW8 / MW8-ST
MSD assays. Aggregated HTT(1–97)-Q46 was included as control. While both assays showed
a dose-dependent detection of aggregated HTT(1–97)-Q46, no signals were observed for
polyQ46 aggregates. Error bars represent standard deviations for three independent measure-
ments (A-C) or three replicate measurements (D-F). In some cases, error bars are too small to
be visible.
(TIF)
S6 Fig. Spike recovery in tissue matrix. A standard curve of HTT(1–97)-Q46 aggregated for
24 h at 37˚C was analyzed in buffer or spiked with 1 mg/mL of a wildtype mouse whole brain
lysate as background matrix in the (A) MW8 / 4C9-ST and (B) MW8 / MW8-ST assays. None
of the assays were significantly affected by the tissue matrix with both buffer and matrix curves
showing a nearly identical signal response. Error bars represent standard deviations for three
independent measurements. In some cases, error bars are too small to be visible.
(TIF)
S7 Fig. Analysis of endogenous mouse HTT levels in an aged series of HD mouse models.
Whole brain lysates of an aged series of (A) R6/2, (B) hetQ175, and (C) BACHD mice were
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analyzed at 0.5 mg/mL (R6/2 and hetQ175) or 1 mg/mL (BACHD) in the pAb147 / 2166 / ST
assay for mouse HTT. While endogenous mouse HTT levels were independent of age and
genotype for R6/2 and BACHD mice, hetQ175 mice showed approximately half the amount of
mouse HTT in comparison to respective wild type animals, as the mouse specific assays does
not recognize the mutant human/mouse chimeric allele. Background: signal generated by sam-
ple buffer. Error bars represent standard deviations of at least three biological replicates. Sam-
ples were compared based on a one-way ANOVA statistical analysis: � p< 0.05, ����
p< 0.0001, n.s. not significant.
(TIF)
S8 Fig. Calibration of the Superose 6 SEC column using recombinant HTT standards.
500 μL of (A) MBP-tagged monomeric HTT(1–97)-Q46, (B) thrombin-digested, aggregated
HTT(1–97)-Q46, and full-length HTT (C) HTT-Q17 and (D) Q46 were run on a Superose 6
SEC column at the given concentrations. Here, proteins were separated by size, with larger
proteins found in earlier elution fractions. Elution fractions were analyzed in the 2B7 /
MW1-ST and/or 2B7 / 4C9-ST assays for human (m)HTT, and the aggregate-selective assays
MW8 / 4C9-ST and MW8 / MW8-ST. Aggregated HTT(1–97)-Q46 eluted first at ~ 8 mL, full-
length HTT-Q17 and Q46 (Mw: 347 and 351 kDa) showed the maximum elution at ~ 11–12
mL, MBP-HTT(1–97)-Q46 (Mw: 58 kDa) eluted last at ~ 16 mL. Curve shapes were smoothed.
Confirmation of detected HTT species by Western blotting of individual elution fractions
failed as samples were too dilute after SEC.
(TIF)
S9 Fig. Intrastriatal adenoviral-delivery of ZFP targeting mutant HTT resulted in reduction
of HTT aggregates in zQ175 mice. (A) and (B) Schematic representation of ZFP viral vectors:
(A) phsyn1-HTT-ZFP30640, (B) ZFP control constructs lacking DNA binding domain, phsyn1-
HTT-ZFP-ΔDBD; ITR: inverted terminal repeat, phSyn1: human synapsin1 promoter, ZFP: zinc
finger protein, WPRE: woodchuck hepatitis virus posttranscriptional regulatory element, A: polyA
sequence, ΔDBD: sequence lacking DNA binding domain. (C and D) Representative images
showing mEM48 immunostaining in striatal tissue from heterozygous zQ175 mice injected with
(C) AAV-SWB-ZFP30640 and (D) AAV-SWB-ZFP-ΔDBD at 2 months of age and analyzed 4
months post-injection. A strongly reduced HTT inclusions load (mEM48-ir) was observed for
AAV-transduced (FLAG+) neurons (NeuN-ir) in ZFP30640-treated animals in comparison with
the ΔDBD control. Quantitative analysis of the images shows marked reduction of perinuclear
HTT inclusions (E) and nuclear mEM48 granularity (texture) in ZPF30640-treated animals (F).
(TIF)
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